Listen to Medscape InDiscussion: Multiple Myeloma, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/964336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Medscape InDiscussion: Multiple Myeloma
Claim This Podcastby Medscape
5.0(4 reviews)
12 episodes
Updated Inactive
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
Listen to Medscape InDiscussion: Multiple Myeloma, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/964336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Language
🇺🇲
Publishing Since
5/3/2022
1 verified contact email on file for Medscape InDiscussion: Multiple Myeloma
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
December 18, 2025
S2 Episode 6: What Is the Future of Multiple Myeloma?
<p>Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting myeloma, frontline therapy, and durable responses.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002718. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Multiple Myeloma https://emedicine.medscape.com/article/204369-overview</p> <p>Updated Diagnostic Criteria and Staging System for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/27249749/</p> <p>Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report https://pubmed.ncbi.nlm.nih.gov/33563895/</p> <p>Multiple Myeloma Imaging https://emedicine.medscape.com/article/391742-overview</p> <p>Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis https://pubmed.ncbi.nlm.nih.gov/34299097/</p> <p>Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/</p> <p>Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage https://pubmed.ncbi.nlm.nih.gov/34857730/</p> <p>Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/40214184/</p> <p>Genomic Landscape of Multiple Myeloma and Its Precursor Conditions https://pubmed.ncbi.nlm.nih.gov/40399554/ </p> <p>Quadruplet Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39348665/</p> <p>Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7501</p> <p>Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial https://pubmed.ncbi.nlm.nih.gov/39841461/</p> <p>Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant Is Not a Medically Suitable Treatment https://www.clinicaltrials.gov/study/NCT05561387</p> <p>Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34002066/</p> <p>The Role of CELMoD Agents in Multiple Myeloma https://pmc.ncbi.nlm.nih.gov/articles/PMC12399888/</p> <p>Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: REDIRECTT-1 https://library.ehaweb.org/eha/2025/eha2025-congress/4173809/shaji.kumar.phase.2.study.of.talquetamab.2B.teclistamab.in.patients.with.html</p> <p>Discovery of a Novel Class NSD2 Inhibitor for Multiple Myeloma With t(4;14) https://pubmed.ncbi.nlm.nih.gov/40949769/</p> <p>Long-Term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7507</p>
November 20, 2025
S2 Episode 5: Is It Time to Screen for Multiple Myeloma?
<p>Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can learn from the iStopMM study.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002717. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Multiple Myeloma https://emedicine.medscape.com/article/204369-overview</p> <p>Screening in Multiple Myeloma and Its Precursors: Are We There Yet? https://pubmed.ncbi.nlm.nih.gov/38175579/</p> <p>Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM): A Population-Based Screening Study for Monoclonal Gammopathy of Undetermined Significance and Randomized Controlled Trial of Follow-Up Strategies https://pubmed.ncbi.nlm.nih.gov/34001889/</p> <p>Identifying Associations Between Race and Gender in the Incidence and Mortality of Patients With Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e20052</p> <p>Revisiting Wilson and Jungner in the Genomic Age: A Review of Screening Criteria Over the Past 40 Years https://pubmed.ncbi.nlm.nih.gov/18438522/</p> <p>International Myeloma Foundation https://www.myeloma.org/</p> <p>Prevalence of Monoclonal Gammopathy of Undetermined Significance https://pubmed.ncbi.nlm.nih.gov/16571879/</p> <p>Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/</p> <p>Prevalence and Risk of Progression of Light-Chain Monoclonal Gammopathy of Undetermined Significance: A Retrospective Population-Based Cohort Study https://pubmed.ncbi.nlm.nih.gov/20472173/</p> <p>Mode of Progression in Smoldering Multiple Myeloma: A Study of 406 Patients https://pubmed.ncbi.nlm.nih.gov/38228628/</p> <p>Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/</p>
October 22, 2025
S2 Episode 4: Should You Treat Smoldering Multiple Myeloma?
<p>Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent studies and shared decision-making.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002716. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/</p> <p>Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/</p> <p>From Criteria to Clinic: How Updated Slim CRAB Criteria Influence Multiple Myeloma Diagnostic Activity https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.7556</p> <p>International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM) https://pubmed.ncbi.nlm.nih.gov/33067414/</p> <p>Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/39652675/</p> <p>Lenalidomide-Dexamethasone Versus Observation in High-Risk Smoldering Myeloma After 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study https://pubmed.ncbi.nlm.nih.gov/36067617/</p> <p>Long-Term Outcome With Lenalidomide and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/23648667/</p> <p>CD38-Directed Therapies for Management of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/34235096/</p> <p>Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma – Results of the Ascent Trial https://ashpublications.org/blood/article/140/Supplement%201/1830/492739/Fixed-Duration-Therapy-with-Daratumumab</p> <p>Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (Krd) Followed by Transplant, Krd Consolidation, and Rd Maintenance https://pubmed.ncbi.nlm.nih.gov/39038268/</p> <p>Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma https://ashpublications.org/blood/article/144/Supplement%201/1027/531466/Early-Safety-and-Efficacy-of-CAR-T-Cell-Therapy-in</p>
12 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Medscape InDiscussion: Multiple Myeloma
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Medscape InDiscussion: Multiple Myeloma?
- How often does this podcast release new episodes?
This podcast updates inactive.
- Where can I listen to this podcast?
This podcast is available on 2 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.